BCL2 and carcinoma: Furthermore, several melanocyte differentiation-related genes, namely the anti-apoptotic gene BCL2, a known MITF target [35], and BLOC1S5, the mutation of which is associated with defects in pigmentation [36], also displayed melanoma-specific ZEB1 binding peaks, further supporting lineage specificity of ZEB1 binding in melanoma cells compared to carcinoma cells.